What’s new: More Chinese residents will have access to U.S. pharma giant Pfizer Inc.’s Paxlovid as China looks to meet the high demand for the Covid drug, according to an infectious disease expert.
The country’s Covid playbook recommends three antiviral drugs, including Paxlovid, which will be “gradually made available at all medical institutions and at the community level,” said Wang Guiqiang, head of the infectious diseases department at Peking University First Hospital, during a press conference held by the State Council Tuesday.
